465 related articles for article (PubMed ID: 32578850)
1. A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial.
Brown AJM; Gandy S; McCrimmon R; Houston JG; Struthers AD; Lang CC
Eur Heart J; 2020 Sep; 41(36):3421-3432. PubMed ID: 32578850
[TBL] [Abstract][Full Text] [Related]
2. Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study.
Brown AJM; Lang C; McCrimmon R; Struthers A
BMC Cardiovasc Disord; 2017 Aug; 17(1):229. PubMed ID: 28835229
[TBL] [Abstract][Full Text] [Related]
3. Allopurinol reduces left ventricular mass in patients with type 2 diabetes and left ventricular hypertrophy.
Szwejkowski BR; Gandy SJ; Rekhraj S; Houston JG; Lang CC; Morris AD; George J; Struthers AD
J Am Coll Cardiol; 2013 Dec; 62(24):2284-93. PubMed ID: 23994420
[TBL] [Abstract][Full Text] [Related]
4. A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial.
Mohan M; Al-Talabany S; McKinnie A; Mordi IR; Singh JSS; Gandy SJ; Baig F; Hussain MS; Bhalraam U; Khan F; Choy AM; Matthew S; Houston JG; Struthers AD; George J; Lang CC
Eur Heart J; 2019 Nov; 40(41):3409-3417. PubMed ID: 30993313
[TBL] [Abstract][Full Text] [Related]
5. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
[TBL] [Abstract][Full Text] [Related]
6. Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial).
Soliman EZ; Ambrosius WT; Cushman WC; Zhang ZM; Bates JT; Neyra JA; Carson TY; Tamariz L; Ghazi L; Cho ME; Shapiro BP; He J; Fine LJ; Lewis CE;
Circulation; 2017 Aug; 136(5):440-450. PubMed ID: 28512184
[TBL] [Abstract][Full Text] [Related]
7. A nutraceutical combination reduces left ventricular mass in subjects with metabolic syndrome and left ventricular hypertrophy: A multicenter, randomized, double-blind, placebo-controlled trial.
Mercurio V; Pucci G; Bosso G; Fazio V; Battista F; Iannuzzi A; Brambilla N; Vitalini C; D'Amato M; Giacovelli G; Vaudo G; Schillaci G; Galletti F; Bonaduce D
Clin Nutr; 2020 May; 39(5):1379-1384. PubMed ID: 31371114
[TBL] [Abstract][Full Text] [Related]
8. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
Bolinder J; Ljunggren Ö; Kullberg J; Johansson L; Wilding J; Langkilde AM; Sugg J; Parikh S
J Clin Endocrinol Metab; 2012 Mar; 97(3):1020-31. PubMed ID: 22238392
[TBL] [Abstract][Full Text] [Related]
9. Systolic left ventricular function according to left ventricular concentricity and dilatation in hypertensive patients: the Losartan Intervention For Endpoint reduction in hypertension study.
Bang CN; Gerdts E; Aurigemma GP; Boman K; Dahlöf B; Roman MJ; Køber L; Wachtell K; Devereux RB
J Hypertens; 2013 Oct; 31(10):2060-8. PubMed ID: 23838656
[TBL] [Abstract][Full Text] [Related]
10. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
Nassif ME; Windsor SL; Tang F; Khariton Y; Husain M; Inzucchi SE; McGuire DK; Pitt B; Scirica BM; Austin B; Drazner MH; Fong MW; Givertz MM; Gordon RA; Jermyn R; Katz SD; Lamba S; Lanfear DE; LaRue SJ; Lindenfeld J; Malone M; Margulies K; Mentz RJ; Mutharasan RK; Pursley M; Umpierrez G; Kosiborod M
Circulation; 2019 Oct; 140(18):1463-1476. PubMed ID: 31524498
[TBL] [Abstract][Full Text] [Related]
11. Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive patients.
Bang CN; Gerdts E; Aurigemma GP; Boman K; de Simone G; Dahlöf B; Køber L; Wachtell K; Devereux RB
Circ Cardiovasc Imaging; 2014 May; 7(3):422-9. PubMed ID: 24723582
[TBL] [Abstract][Full Text] [Related]
12. Lack of reduction of left ventricular mass in treated hypertension: the strong heart study.
de Simone G; Devereux RB; Izzo R; Girfoglio D; Lee ET; Howard BV; Roman MJ
J Am Heart Assoc; 2013 Jun; 2(3):e000144. PubMed ID: 23744404
[TBL] [Abstract][Full Text] [Related]
13. A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study.
Cooper GJ; Young AA; Gamble GD; Occleshaw CJ; Dissanayake AM; Cowan BR; Brunton DH; Baker JR; Phillips AR; Frampton CM; Poppitt SD; Doughty RN
Diabetologia; 2009 Apr; 52(4):715-22. PubMed ID: 19172243
[TBL] [Abstract][Full Text] [Related]
14. The relation between peripheral vascular structure, left ventricular hypertrophy, and ambulatory blood pressure in essential hypertension.
Sihm I; Schroeder AP; Aalkjaer C; Holm M; Mørn B; Mulvany M; Thygesen K; Lederballe O
Am J Hypertens; 1995 Oct; 8(10 Pt 1):987-96. PubMed ID: 8845080
[TBL] [Abstract][Full Text] [Related]
15. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial.
Karg MV; Bosch A; Kannenkeril D; Striepe K; Ott C; Schneider MP; Boemke-Zelch F; Linz P; Nagel AM; Titze J; Uder M; Schmieder RE
Cardiovasc Diabetol; 2018 Jan; 17(1):5. PubMed ID: 29301520
[TBL] [Abstract][Full Text] [Related]
16. Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes.
Lundkvist P; Sjöström CD; Amini S; Pereira MJ; Johnsson E; Eriksson JW
Diabetes Obes Metab; 2017 Jan; 19(1):49-60. PubMed ID: 27550386
[TBL] [Abstract][Full Text] [Related]
17. [Blood pressures values during evaluation of 24-h ambulatory blood pressure monitoring and left ventricular hypertrophy in patients with chronic renal failure treated with hemodialysis (HD)].
Wanic-Kossowska M; Leman P; Kobelski M; Czekalski S
Pol Arch Med Wewn; 2002 Jan; 107(1):29-35. PubMed ID: 12046341
[TBL] [Abstract][Full Text] [Related]
18. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study.
Eriksson JW; Lundkvist P; Jansson PA; Johansson L; Kvarnström M; Moris L; Miliotis T; Forsberg GB; Risérus U; Lind L; Oscarsson J
Diabetologia; 2018 Sep; 61(9):1923-1934. PubMed ID: 29971527
[TBL] [Abstract][Full Text] [Related]
19. Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF.
Inzucchi SE; Docherty KF; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Solomon SD; Verma S; Bělohlávek J; Böhm M; Chiang CE; de Boer RA; Diez M; Dukát A; Ljungman CEA; Bengtsson O; Langkilde AM; Sjöstrand M; Jhund PS; McMurray JJV;
Diabetes Care; 2021 Feb; 44(2):586-594. PubMed ID: 33355302
[TBL] [Abstract][Full Text] [Related]
20. A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation.
Ott C; Jumar A; Striepe K; Friedrich S; Karg MV; Bramlage P; Schmieder RE
Cardiovasc Diabetol; 2017 Feb; 16(1):26. PubMed ID: 28231831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
